Merck & Co., Inc. CEO Rob Davis told investors the launch of Winrevair (sotatercept) for the treatment of pulmonary arterial hypertension (PAH) is progressing as expected in its early days, with the drug poised to become one of the company’s future growth drivers to help reduce its dependence on Keytruda (pembrolizumab).
Merck Investors Keeping A Close Watch On Winrevair Uptake
Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance.
